These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 16844360

  • 1. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y, Lee SH, Sinko PJ.
    Eur J Pharm Sci; 2006 Oct 01; 29(2):102-10. PubMed ID: 16844360
    [Abstract] [Full Text] [Related]

  • 2. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
    Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 4. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F, Fan D, Qi J, Zhu H, Zhou Y, Yang C, Zhu Z, Xiong D.
    Life Sci; 2008 Sep 26; 83(13-14):496-501. PubMed ID: 18725232
    [Abstract] [Full Text] [Related]

  • 5. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, Wei MJ.
    Cancer Lett; 2013 Oct 01; 339(1):107-15. PubMed ID: 23879965
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M.
    Int J Cancer; 2006 Jul 15; 119(2):414-22. PubMed ID: 16646006
    [Abstract] [Full Text] [Related]

  • 9. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F.
    Cancer Res; 2001 Aug 15; 61(16):6034-7. PubMed ID: 11507048
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN, Vangara KK, Palakurthi S.
    Anticancer Res; 2014 Nov 15; 34(11):6345-51. PubMed ID: 25368234
    [Abstract] [Full Text] [Related]

  • 11. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N, Yuan J, Liu J, Tian S.
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec 15; 42(12):854-62. PubMed ID: 21106767
    [Abstract] [Full Text] [Related]

  • 12. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
    Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, Morrow CS.
    Cancer Res; 2001 Jul 15; 61(14):5461-7. PubMed ID: 11454692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH.
    Ann N Y Acad Sci; 2000 Jul 15; 922():188-94. PubMed ID: 11193894
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU.
    Hematology; 2009 Aug 15; 14(4):204-12. PubMed ID: 19635183
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
    Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956
    [Abstract] [Full Text] [Related]

  • 19. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L, Ross DD.
    Oncogene; 2003 Oct 20; 22(47):7340-58. PubMed ID: 14576842
    [Abstract] [Full Text] [Related]

  • 20. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
    Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW.
    Neoplasma; 2005 Oct 20; 52(3):219-24. PubMed ID: 15875083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.